Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | EOL-1; EOL1; EoL-1-cell; EoL-1 cell; AML-EOL-1 |
| Species | Human |
| Cat.No | ABC-TC440S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphoblast |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Blood |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
The growth rate of EoL-1 cells is notably slow, necessitating up to five days for optimal subculture conditions. Cellular growth predominantly occurs in the form of large clusters, with confluence indicators encompassing changes in culture media color and the health status of central cells. For optimal maintenance, a cautious and minimally disruptive handling approach is advised.
Why choose EoL-1 cell from AcceGen?
EoL-1 cells from AcceGen exhibit high viability and quality, maintaining sterility and freedom from mycoplasma contamination. They have been rigorously tested and confirmed negative for EBV, HBV, HCV, HHV-8, HIV-1, HIV-2, HTLV-1/2, MLV, and SMRV. Additionally, their identity has been verified through STR analysis.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The EoL-1 cell line, specializing in the eosinophilic lineage, offers a valuable in vitro platform for the comprehensive investigation of malignant eosinophilic characteristics, making it a crucial asset for unraveling various aspects of eosinophil-related diseases. Moreover, EoL-1 cells provide a reliable model for delving into the functions and regulatory mechanisms of human eosinophils. Notably, this cell line has played a pivotal role in exploring the therapeutic potential of AGS67E, an antibody-drug conjugate targeting CD37 for the treatment of B/T-cell malignancies, as well as evaluating the efficacy of anti-vascular cell adhesion molecule-1 (VCAM-1) monoclonal antibodies in mitigating asthma, as demonstrated in a murine asthma model.
